US Pharma MarketingMixed Phase 3 data for camlipixant prompted the British pharma to cease development, making the drug the third from its class to fail.
GSK shelves cough drug acquired in $2B deal
Mixed Phase 3 data for camlipixant prompted the British pharma to cease development, making the drug the third from its class to fail.
Source: BioPharma Dive